Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Development and pilot testing of a conversation aid to support the evaluation of patients with thyroid nodules
Ospina, Naykky Singh , Bagautdinova, Diliara , Hargraves, Ian , Barb, Diana , Subbarayan, Sreevidya, Srihari, Ashok, Bylund, Carma L. , Treise, Debbie, Brito, Juan P. , Ospina, Naykky Singh , Barb, Diana , Singh Ospina, Naykky M , Singh Ospina, Naykky , Brito, Juan P , Wang, Shu , Maraka, Spyridoula , Montori, Víctor M.

Mayo Clinic

Clinical Endocrinology | September 30, 2021 | Volume: 96 | Issue: 4 | Pages: 627-636

10.1111/cen.14599 | PMID 34590734 Get It

AbstractObjectiveTo support patient‐centred care and the collaboration of patients and clinicians, we developed and pilot tested a conversation aid for patients with thyroid nodules.Design, Patient and MeasurementsWe developed a web‐based Thyroid NOdule Conversation aid (TNOC) following a human‐centred design. A proof of concept observational pre–post study was conducted (TNOC vs. usual care [UC]) to assess the impact of TNOC on the quality of conversations. Data sources included recordings of clinical visits, post‐encounter surveys and review of electronic health records. Summary statistics and group comparisons are reported.ResultsSixty‐five patients were analysed (32 in the UC and 33 in the TNOC cohort). Most patients were women (89%) with a median age of 57 years and were incidentally found to have a thyroid nodule (62%). Most thyroid nodules were at low risk for thyroid cancer (71%) and the median size was 1.4 cm. At baseline, the groups were similar except for higher numeracy in the TNOC cohort. The use of TNOC was associated with increased involvement of patients in the decision‐making process, clinician satisfaction and discussion of relevant topics for decision making. In addition, decreased decisional conflict and fewer thyroid biopsies as the next management step were noted in the TNOC cohort. No differences in terms of knowledge transfer, length of consultation, thyroid cancer risk perception or concern for thyroid cancer diagnosis were found.ConclusionIn this pilot observational study, using TNOC in clinical practice was feasible and seemed to help the collaboration of patients and clinicians.
Defining Proximity Proteome of Histone Modifications by Antibody-Mediated Protein A-APEX2 Labeling
Li, Xinran , Zhou, Jiaqi , Zhao, Wenjuan , Wen, Qing , Wang, Weijie , Peng, Huipai , Gao, Yuan , Bouchonville, Kelly J. , Offer, Steven M. , Chan, Kui Ming , Wang, Zhiquan , Li, Nan , Gan, Haiyun , Offer, Steven M , Wang, Zhiquan

Mayo Clinic

Genomics, Proteomics & Bioinformatics | September 30, 2021 | Volume: 20 | Issue: 1 | Pages: 87-100

10.1016/j.gpb.2021.09.003 | PMID 34555496 Get It

Abstract Proximity labeling catalyzed by promiscuous enzymes, such as APEX2, has emerged as a powerful approach to characterize multiprotein complexes and protein–protein interactions. However, current methods depend on the expression of exogenous fusion proteins and cannot be applied to identify proteins surrounding post-translationally modified proteins. To address this limitation, we developed a new method to label proximal proteins of interest by antibody-mediated protein A-ascorbate peroxidase 2 (pA-APEX2) labeling (AMAPEX). In this method, a modified protein is bound in situ by a specific antibody, which then tethers a pA-APEX2 fusion protein. Activation of APEX2 labels the nearby proteins with biotin; the biotinylated proteins are then purified using streptavidin beads and identified by mass spectrometry. We demonstrated the utility of this approach by profiling the proximal proteins of histone modifications including H3K27me3, H3K9me3, H3K4me3, H4K5ac, and H4K12ac, as well as verifying the co-localization of these identified proteins with bait proteins by published ChIP-seq analysis and nucleosome immunoprecipitation. Overall, AMAPEX is an efficient method to identify proteins that are proximal to modified histones.
IL-23 amplifies the epithelial-mesenchymal transition of mechanically conditioned alveolar epithelial cells in rheumatoid arthritis-associated interstitial lung disease through mTOR/S6 signaling
Zhang, Chujie , Wang, Shaohua , Lau, Jessica, Roden, Anja C. , Matteson, Eric L. , Tschumperlin, Daniel J. , Vassallo, Robert , Tschumperlin, Daniel J , Vassallo, Robert , Sun, Jie , Luo, Fengming

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 29, 2021 | Volume: 321 | Issue: 6 | Pages: L1006-L1022

10.1152/ajplung.00292.2021 | PMID 34585990 Get It

Epithelial-mesenchymal transition (EMT) creates an environment facilitating fibrosis following alveolar epithelial cell injury. IL-23 has important roles in chronic autoimmune conditions like rheumatoid arthritis (RA), but its role in the interstitial lung disease that affects patients with RA is unclear. This study aimed to determine the profibrogenic role of IL-23 on somatic alveolar type I (ATI) epithelial cells. Primary ATI cells were isolated from rats and cultured on plastic dishes for 1–3 wk. After prolonged culture (≥14 days) on rigid culture dishes, primary ATI cells gradually acquired a mesenchymal phenotype, identified by decreased expression of caveolin-1, and reorganization of F-actin cytoskeleton, indicating the initiation of EMT by matrix stiffness. To determine how IL-23 promotes EMT in vitro, transitioning ATI cells, cultured on a stiff substrate for ≥14 days were stimulated with IL-23. The EMT phenotype was significantly enhanced by IL-23, which upregulated α-smooth muscle actin (α-SMA), collagen I/III protein, and decreased caveolin-1. Furthermore, IL-23 significantly promoted cell invasion, as well as apoptotic resistance on transitioning ATI cells. Mechanistically, IL-23-induced EMT was mammalian target of rapamycin/ribosomal protein S6 (mTOR/S6) signaling dependent and reversible by rapamycin. Transcriptional sequencing analysis of human lung fibrosis biopsy tissue revealed key roles for IL-23 in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). This result was further validated by significantly upregulated IL-23 expression at the mRNA level in RA-ILD lung sections. Notably, transitioning ATI epithelial cells were abundantly detected in RA-ILD tissue. Taken together, these data support a role for IL-23 in the pathogenesis of RA lung fibrosis by promoting EMT in alveolar epithelial cells through mTOR/S6 signaling.
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, Chia‐Chen , Murray, Melissa E. , Li, Xia , Zhao, Na , Wang, Na , Shue, Francis , Martens, Yuka A. , Li, Yonghe , Raulin, Ana‐Caroline , Rosenberg, Cassandra L. , Doss, Sydney V. , Wren, Melissa C. , Jia, Lin , Ren, Yingxue , Ikezu, Tadafumi C. , Lü, Wenyan, Trottier, Zachary A. , Chen, Yixing , Linares, Cynthia , Wang, Xue , Kurti, Aishe, Asmann, Yan W. , Vemuri, Prashanthi , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Parisi, Joseph E., Ferman, Tanis J. , Graff‐Radford, Neill R. , Petersen, Ronald C. , Younkin, Steven G. , Fryer, John Denis , Frieden, Carl , Ross, Owen A. , Bu, Guojun , Shue, Francis , Atagi, Yuka , Raulin, Ana-Caroline , Doss, Sydney V , Zhao, Jing , Wren, Melissa C , Ikezu, Tadafumi C , Caulfield, Thomas R , Trottier, Zachary A , Wszolek, Z.K. , Smith, Glenn E. , Vemuri, Prashanthi , Jack, Clifford R , Ferman, Tanis J , Boeve, Brad , Petersen, Ronald C , Younkin, Steven , Frieden, Carl , Dickson, Dennis W , Ross, Owen A , Bu, Guojun , Liu, Chia-Chen , Kantarci, Kejal , Murray, Melissa E , Zhao, Na , Chen, Yixing , Heckman, Michael G. , Zhao, Jing , Fu, Yuan , Caulfield, Thomas R. , Knight, Joshua A. , Wszołek, Zbigniew K. , Knopman, David S. , Boeve, Bradley F. , Wang, Hu , Han, Xianlin , Dickson, Dennis W.

Mayo Clinic

Science Translational Medicine | September 29, 2021 | Volume: 13 | Issue: 613 | Pages: No page available

10.1126/scitranslmed.abc9375 | PMID 34586832 Get It

A rare APOE variant APOE3 -Jac reduces self-aggregation and promotes healthy brain aging.
Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Lin, Sinan , Mao, Ren , Qian, Chenchen , Wang, Jie , Bruining, David H. , Feagan, Brian G. , Chen, Minhu , Rieder, Florian , Rieder, Florian , Bettenworth, Dominik , Li, Jiannan , Jairath, Vipul

Mayo Clinic

Physiological Reviews | September 27, 2021 | Volume: 102 | Issue: 2 | Pages: 605-652

10.1152/physrev.00005.2021 | PMID 34569264 Get It

Intestinal fibrosis is considered an inevitable complication of Crohn’s disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress in the management of stricturing CD is hampered by the lack of effective antifibrotic therapy; however, this situation is likely to change because of recent advances in other fibrotic diseases of the lung, liver, and skin. In this review, we summarize data from randomized controlled trials (RCTs) of antifibrotic therapies in these conditions. Multiple compounds have been tested for antifibrotic effects in other organs. According to their mechanisms, they were categorized into growth factor modulators, inflammation modulators, 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, intracellular enzymes and kinases, renin-angiotensin system (RAS) modulators, and others. From our review of the results from the clinical trials and discussion of their implications in the gastrointestinal tract, we have identified several molecular candidates that could serve as potential therapies for intestinal fibrosis in CD.
Primary CNS Lymphoma and Secondary Causes of Mania: A Case Report and Literature Review
Wang, Chris , Fipps, David C. , Fipps, David C

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | September 27, 2021 | Volume: 34 | Issue: 1 | Pages: 84-88

10.1176/appi.neuropsych.21030084 | PMID 34565169 Get It

Emerging concepts in endoscopic skull base surgery training
Rabinowitz, Mindy, Patel, Zara M. , McKinney, Kibwei A. , Signore, Anthony G. Del, Ebert, Charles S. , Thorp, Brian D. , Choby, Garret , Patel, Zara , Wang, Eric W , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | September 27, 2021 | Volume: 11 | Issue: 12 | Pages: 1611-1616

10.1002/alr.22895 | PMID 34569168 Get It

Does reduction of the Meyerding grade correlate with outcomes in patients undergoing decompression and fusion for grade I degenerative lumbar spondylolisthesis?
Chan, Andrew K. , Mummaneni, Praveen V. , Burke, John F. , Mayer, Rory , Bisson, Erica F. , Rivera, Joshua, Pennicooke, Brenton , Fu, Kai-Ming, Park, Paul , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Wang, Michael Y. , Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Haid, Regis W., Chou, Dean , Alvi, Mohammed A, Alvi, Mohammed Ali , Guan, Jian

Mayo Clinic

Journal of Neurosurgery: Spine | September 25, 2021 | Volume: 36 | Issue: 2 | Pages: 177-184

10.3171/2021.3.spine202059 | PMID 34534963 Get It

OBJECTIVE Reduction of Meyerding grade is often performed during fusion for spondylolisthesis. Although radiographic appearance may improve, correlation with patient-reported outcomes (PROs) is rarely reported. In this study, the authors’ aim was to assess the impact of spondylolisthesis reduction on 24-month PRO measures after decompression and fusion surgery for Meyerding grade I degenerative lumbar spondylolisthesis. METHODS The Quality Outcomes Database (QOD) was queried for patients undergoing posterior lumbar fusion for spondylolisthesis with a minimum 24-month follow-up, and quantitative correlation between Meyerding slippage reduction and PROs was performed. Baseline and 24-month PROs, including the Oswestry Disability Index (ODI), EQ-5D, Numeric Rating Scale (NRS)–back pain (NRS-BP), NRS-leg pain (NRS-LP), and satisfaction (North American Spine Society patient satisfaction questionnaire) scores were noted. Multivariable regression models were fitted for 24-month PROs and complications after adjusting for an array of preoperative and surgical variables. Data were analyzed for magnitude of slippage reduction and correlated with PROs. Patients were divided into two groups: < 3 mm reduction and ≥ 3 mm reduction. RESULTS Of 608 patients from 12 participating sites, 206 patients with complete data were identified in the QOD and included in this study. Baseline patient demographics, comorbidities, and clinical characteristics were similarly distributed between the cohorts except for depression, listhesis magnitude, and the proportion with dynamic listhesis (which were accounted for in the multivariable analysis). One hundred four (50.5%) patients underwent lumbar decompression and fusion with slippage reduction ≥ 3 mm (mean 5.19, range 3 to 11), and 102 (49.5%) patients underwent lumbar decompression and fusion with slippage reduction < 3 mm (mean 0.41, range 2 to −2). Patients in both groups (slippage reduction ≥ 3 mm, and slippage reduction < 3 mm) reported significant improvement in all primary patient reported outcomes (all p < 0.001). There was no significant difference with regard to the PROs between patients with or without intraoperative reduction of listhesis on univariate and multivariable analyses (ODI, EQ-5D, NRS-BP, NRS-LP, or satisfaction). There was no significant difference in complications between cohorts. CONCLUSIONS Significant improvement was found in terms of all PROs in patients undergoing decompression and fusion for lumbar spondylolisthesis. There was no correlation with clinical outcomes and magnitude of Meyerding slippage reduction.
Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
Lehrer, Eric J. , Stoltzfus, Kelsey C. , Walter, Vonn , Louie, Alexander V. , Walter, Vonn , Jones, Brianna M. , Gusani, Niraj J. , Wang, Ming , Trifiletti, Daniel M. , Siva, Shankar , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | September 24, 2021 | Volume: 44 | Issue: 11 | Pages: 572-579

10.1097/coc.0000000000000866 | PMID 34560720 Get It

Objectives: Metastatic cancer has historically been considered fatal; however, there is a paucity of evidence characterizing the epidemiology of incidence, treatment, and outcomes in these patients. Materials and Methods: Incidence rates, annual percent change (APC), descriptive epidemiological statistics, and odds ratios for survival were calculated using registry data from the Surveillance, Epidemiology, and End Results (SEER) and the National Cancer Database (NCDB), 1998 to 2015. Results: There were a total of 1,055,860 patients with metastatic cancer. The most frequent primary cancers were lung (42.6%), colorectal (9.5%), and ovarian (5.5%). Metastatic lung and colorectal cancer incidence decreased, APC: −1.57 (P<0.001) and APC: −1.48 (P<0.001), respectively; metastatic pancreatic cancer incidence increased, APC: 0.62 (P=0.001). The use of local therapies decreased for almost all sites, and the use of systemic therapies increased across multiple sites: single-agent chemotherapy in kidney (2.54% increase/year), female breast (1.14% increase/year), and prostate cancer (1.08% increase/year); multiagent chemotherapy, most notably in pancreas (2.23% increase/year), uterus (1.81% increase/year), and colorectal cancer (1.54% increase/year). Increased utilization of immunotherapy was observed across the majority of sites, most notably in melanoma (2.14% increase/year). Patients diagnosed from 2006 to 2010 had 17.4% higher odds of surviving at least 60 months compared with 1998 to 2002. Conclusions: In this study, metastatic disease has been shown to have unique epidemiological patterns, and survival has improved. Continued research on metastatic disease is important in understanding and addressing the distinct health concerns of this population.
Radiomics Derived Brain Age Predicts Functional Outcome After Acute Ischemic Stroke
Bretzner, Martin , Bonkhoff, Anna K. , Schirmer, Markus D. , Hong, Sung‐Min , Donahue, Kathleen, Etherton, Mark R. , Rist, Pamela M. , Nardin, Marco, Regenhardt, Robert W. , Leclerc, X. , Gautherot, Morgan , Wang, Clinton, Benavente, Oscar, Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , McArdle, Patrick, Rolfs, Arndt , Schmidt, Reinhold, Sharma, Pankaj , Słowik, Agnieszka , Sousa, Alessandro Viana Oliveira e, Strbian, Daniel , Wassélius, Johan , Woo, Daniel , Worrall, Bradford B. , Maguire, Jane , Golland, Polina , Kuchcinski, Grégory , Rost, Natalia S. , Bretzner, Martin , Strbian, Daniel , Regenhardt, Robert W , Dalca, Adrian Vasile , Giese, Anne‐Katrin , Lopes, Renaud , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Jood, Katarina , Lemmens, Robin , Levi, Christopher , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Sousa, Alessandro Augusto Viana Oliveira e, Stanne, Tara M. , Tatlisumak, Turgut , Thijs, Vincent , Vagal, Achala , Wu, Ona , Zand, Ramin , Lindgren, Arne G. , Jern, Christina

Mayo Clinic

No container title available | September 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-923769/v1 Get It

Abstract While chronological age is one of the most influential determinants of post-stroke outcomes, little is known of the impact of neuroimaging-derived biological brain age. We here first examine whether radiomics analysis of the texture of brain T2-FLAIR MRI images can be used to predict brain age in stroke patients. We then assess the clinical determinants of accelerated brain aging and, finally, its impact on post-stroke functional outcomes. Leveraging a multisite cohort of 4,163 ischemic stroke patients, we show that older-appearing patients have more hypertension, diabetes mellitus, prior strokes, and smoking history and are more likely to develop worse post-stroke outcomes than their younger-appearing counterparts. Our results strengthen the importance of preventive medicine for maintaining brain health in stroke patients as they age and suggest a novel methodology to capture previously undescribed prognostic information available on commonly acquired MRI sequences during routine stroke care.